RIGIN
Solid laboratory evidence but limited human clinical data. Most research comes from cosmetic industry studies rather than independent medical trials.
Primarily studied by cosmetic chemists developing anti-aging skincare products and dermatological researchers investigating inflammatory pathways in skin aging.
Since Feb 2026
14 total, 1 human
What is RIGIN?
This synthetic lipopeptide has become a cornerstone ingredient in commercial anti-aging skincare, most notably as half of the Matrixyl 3000 complex. Dermatological researchers focus on its ability to calm the persistent, low-level inflammation that accelerates visible aging. The peptide's design allows it to penetrate skin layers more effectively than its non-lipidated counterparts.
The peptide works by blocking the production of interleukin-6, a key inflammatory messenger that skin cells release when stressed or damaged. Think of IL-6 as an alarm signal that, when constantly triggered, keeps skin in a state of chronic irritation that breaks down collagen and elastin. By muting this inflammatory chatter, the peptide helps maintain the cellular environment needed for healthy skin repair.
What the Research Shows
14 studies with only one human trial limits confidence in real-world effectiveness, though laboratory results appear consistent across multiple research groups.
Notable Studies
Yi L, Song J, Zhang Z et al. · Int J Biol Macromol (2025)
In Vitro
Porras M, Hernández D, Boto A · Int J Mol Sci (2025)
In Vitro
Zhang B, Li Y, Yang P et al. · Viruses (2024)
In Vitro
Zhang B, Xu S, Liu M et al. · Autophagy (2023)
In Vitro
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.